Search

everythinglearnresearchcommunity

for

Search:↓

Stopping methotrexate might reverse lymphoma-like conditions in some patients.

Certain immune markers may predict chemotherapy response in mesothelioma, and nivolumab is a tolerable and effective treatment for advanced non-small cell lung cancer.

Tocilizumab treatment was associated with significant hair regrowth in one patient and temporary hair loss followed by regrowth in another.

Mycophenolate mofetil may improve lupus nephritis remission more than cyclophosphamide but with uncertain safety.

Infliximab was effective in treating a scalp condition that did not respond to other treatments.

Trodelvy™ helped some patients with advanced breast cancer, but had side effects.

Telitacicept effectively improved hair regrowth in a woman with lupus and alopecia.

Etanercept effectively treated a severe skin condition when other treatments failed.

Upadacitinib effectively treats psoriasiform eczema and some related conditions.

A 25-year-old man with multiple skin tumors was successfully treated with acitretin and methotrexate.

Adalimumab improved folliculitis decalvans in most patients.

Increased TEMRA cells can predict treatment outcomes in rapidly progressive alopecia areata.

Recombinant thrombomodulin can effectively treat severe complications in Cronkhite-Canada syndrome.

A medicine called tofacitinib worked to treat a hair loss condition linked with a muscle and skin disease.

Oral tacrolimus helped a rheumatoid arthritis patient regrow hair lost due to alopecia areata.

A patient with alopecia had hair regrowth with tofacitinib but developed a skin reaction, choosing to continue the treatment despite the side effect.

Ritlecitinib shows promise for hair regrowth in alopecia areata patients.

The study created special nanoparticles that effectively deliver an anti-inflammatory drug to treat skin inflammation in psoriasis.

Ritlecitinib effectively treats alopecia areata and is safe for long-term use in people 12 and older.

Upadacitinib improved multiple immune-related conditions in one patient.

Ruxolitinib treatment led to unexpected hair regrowth in a patient with alopecia universalis.

Tofacitinib and low-dose IL-2 may help maintain hair regrowth in alopecia areata without ongoing treatment.

Ritlecitinib effectively maintains hair regrowth in alopecia areata patients.

Ritlecitinib effectively regrows hair in severe alopecia areata and is well tolerated.

Promising cancer treatments were found, but the manufacturer closed.

Both tofacitinib and ruxolitinib are effective and tolerable for treating alopecia areata.

Ruxolitinib helped regrow hair in a woman with a blood disorder and complete hair loss.

Ritlecitinib successfully treated a child's alopecia universalis after baricitinib failed.